Literature DB >> 28554259

Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia.

Cristina Motlló1, Josep-Maria Ribera1, Mireia Morgades1, Isabel Granada1, Pau Montesinos2, Santiago Mercadal3, José González-Campos4, María-José Moreno5, Pere Barba6, Marta Cervera7, Manuel Barrios8, Andrés Novo9, Teresa Bernal10, Jesús-María Hernández-Rivas11, Eugenia Abella12, María-Luz Amigo13, Mar Tormo14, Rodrigo Martino15, Esperanza Lavilla16, Juan Bergua17, Alfons Serrano18, Daniel García-Belmonte19, Ramon Guàrdia20, Javier Grau1, Evarist Feliu1.   

Abstract

About 25-35% of adult patients with acute lymphoblastic leukemia show the Philadelphia (Ph) chromosome. Few series have evaluated the prognosis of additional cytogenetic alterations (ACA) to the Ph chromosome. We analyzed the frequency, type and prognostic significance ofACA in adults (18-60 years) treated in the ALL-Ph-08 trial. Fifty-two out of 74 patients (70%) showed ACA and 19 (26%) presented monosomies associated with t(9;22) (monosomal karyotype, MK). Similar complete response (CR) rate, CR duration, overall survival and event-free survival (EFS) were observed in patients with or without ACA, but patients with MK showed shorter CR duration and EFS than the remaining. On multivariate analysis, the only variable with prognostic impact for CR duration and EFS was the presence of MK (p = .003 and p = .036, respectively). Although ACA associated with the Ph chromosome are frequent, only monosomies were associated with poor prognosis in this group of patients.

Entities:  

Keywords:  Acute lymphoblastic leukemia; Philadelphia chromosome; additional cytogenetic alterations; monosomies; prognosis

Mesh:

Year:  2017        PMID: 28554259     DOI: 10.1080/10428194.2017.1326596

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  7 in total

1.  Cytogenetic aberrations in adult acute lymphoblastic leukemia-A population-based study.

Authors:  Emma Bergfelt Lennmyr; Marie Engvall; Gisela Barbany; Linda Fogelstrand; Hanna Rhodin; Helene Hallböök
Journal:  EJHaem       Date:  2021-09-22

Review 2.  The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone Group of Hematological Cytogenetics (GFCH).

Authors:  F Nguyen-Khac; A Bidet; A Daudignon; M Lafage-Pochitaloff; G Ameye; C Bilhou-Nabéra; E Chapiro; M A Collonge-Rame; W Cuccuini; N Douet-Guilbert; V Eclache; I Luquet; L Michaux; N Nadal; D Penther; B Quilichini; C Terre; C Lefebvre; M-B Troadec; L Véronèse
Journal:  Leukemia       Date:  2022-04-16       Impact factor: 12.883

3.  Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  Anna Lucia Fedullo; Monica Messina; Loredana Elia; Alfonso Piciocchi; Valentina Gianfelici; Alessia Lauretti; Stefano Soddu; Maria Cristina Puzzolo; Clara Minotti; Felicetto Ferrara; Bruno Martino; Patrizia Chiusolo; Valeria Calafiore; Stefania Paolini; Marco Vignetti; Antonella Vitale; Anna Guarini; Robin Foà; Sabina Chiaretti
Journal:  Haematologica       Date:  2018-09-06       Impact factor: 9.941

Review 4.  The role of stem cell transplantation in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  Jose-Maria Ribera; Jordi Ribera; Eulalia Genescà
Journal:  Ther Adv Hematol       Date:  2018-11-22

5.  A prognostic approach on a case of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia with monosomy-7.

Authors:  Hanaa Skhoun; Mohammed Khattab; Aziza Belkhayat; Zahra Takki Chebihi; Nadia Dakka; Jamila El Baghdadi
Journal:  Clin Case Rep       Date:  2021-12-26

Review 6.  Modern Management Options for Ph+ ALL.

Authors:  Josep-Maria Ribera; Sabina Chiaretti
Journal:  Cancers (Basel)       Date:  2022-09-20       Impact factor: 6.575

7.  Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL.

Authors:  Yoshihiro Hatta; Shuichi Mizuta; Keitaro Matsuo; Shigeki Ohtake; Masako Iwanaga; Isamu Sugiura; Noriko Doki; Heiwa Kanamori; Yasunori Ueda; Chikamasa Yoshida; Nobuaki Dobashi; Tomoya Maeda; Toshiaki Yujiri; Fumihiko Monma; Yoshikazu Ito; Fumihiko Hayakawa; Jin Takeuchi; Hitoshi Kiyoi; Yasushi Miyazaki; Tomoki Naoe
Journal:  Ann Hematol       Date:  2018-04-24       Impact factor: 3.673

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.